VYNE Therapeutics (VYNE) CEO Domzalski received 730,000 Stock Option (right to buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
David Domzalski (President and CEO at VYNE Therapeutics Inc., VYNE) reported that they received 730,000 Stock Option (right to buy) on Jan 21, 2025.
- Reporting person
- Domzalski David
- Role
- PRESIDENT AND CEO
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | Grant or award (A) | Stock Option (right to buy)On 730,000 Common Stock1 | +730,000 | - | - | 730,000 direct |
Holdings before and after
- Stock Option (right to buy): 0 to 730,000 direct
Footnotes from the filing
- 1. The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2026 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Domzalski report in this VYNE Form 4?
David Domzalski (President and CEO at VYNE Therapeutics Inc., VYNE) reported that they received 730,000 Stock Option (right to buy) on Jan 21, 2025.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for VYNE
Earlier insider filings at VYNE
- Jan 16, 2025Director Lepore Patrick G bought $43,800 worth of shares (15,000 units at $2.92), increasing direct ownership by 41% to 51,472 units (SEC Form 4)
- Jan 2, 2025CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 4,857 shares, decreasing direct ownership by 4% to 128,637 units (SEC Form 4)
- Jan 2, 2025CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 4,675 shares, decreasing direct ownership by 4% to 126,892 units (SEC Form 4)
- Jan 2, 2025PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 24,536 shares, decreasing direct ownership by 5% to 476,061 units (SEC Form 4)
- Jan 2, 2025CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 4,697 shares, decreasing direct ownership by 3% to 144,329 units (SEC Form 4)
Quantisnow market dataNASDAQ
VYNE
VYNE Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for VYNE
Full VYNE profile on Quantisnow Follow VYNE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time